EQ Jul 2024 2.500 put
| Previous close | 1.8000 |
| Open | 1.8000 |
| Bid | 1.5500 |
| Ask | 2.2000 |
| Strike | 2.50 |
| Expiry date | 2024-07-19 |
| Day's range | 1.8000 - 1.8000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Business WireEquillium to be included in the Russell Microcap® Index
LA JOLLA, Calif., June 12, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effective at the open of equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24.
Business WireEquillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
LA JOLLA, Calif., June 05, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that on May 31, 2024, the Compensation Committee of Equillium’s Board of Directors granted an inducement award consisting of a nonstatutory stock option to purchase 7,200 shares of common stock to a new employee under Equillium’s 2024 Inducement Plan. The Compensation Committee approve
Business WireEquillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata
LA JOLLA, Calif., June 04, 2024--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced positive topline data from its Phase 2, single dose, proof-of-concept (PoC) study of EQ101 in adult patients with moderate, severe or very-severe alopecia areata (AA), an autoimmune disease driven by an immune cell attack of the hair follicles that
